Houston, TX – According to filings with the U.S. Securities and Exchange Commission, Nanospectra Biosciences is raising $11,264,664.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, David Jorden played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Nanospectra Biosciences
Nanospectra Biosciences is a medical device company pioneering a patient-centric use of nanomedicine for selective thermal ablation. AuroLase, the company’s lead product for the ablation of prostate cancer tissue, is the first and only ultra-focal tissue ablation therapy designed to maximize treatment efficacy while minimizing side effects typically associated with surgery, radiation, and traditional focal therapies. Implementing a multi-prong growth strategy, Nanospectra is focusing on clinical advancements, exclusive partnering agreements and ongoing research and development. Nanospectras technology development has been funded to date by a series of grants, private equity investments and corporate partnerships.

To learn more about Nanospectra Biosciences, visit http://www.nanospectra.com/

Contact:
David Jorden, Chief Executive Officer
713-842-2720

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved